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IL-34 mediates acute kidney injury and worsens
subsequent chronic kidney disease
Jea-Hyun Baek,1,2 Rui Zeng,1,2 Julia Weinmann-Menke,3 M. Todd Valerius,2,4 Yukihiro Wada,1,2 Amrendra K. Ajay,2
Marco Colonna,5 and Vicki R. Kelley1,2
Laboratory of Molecular Autoimmune Disease, 2Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 3Department of Nephrology & Rheumatology,

1

Johannes-Gutenberg University Mainz, Mainz, Germany. 4Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. 5Department of Pathology and Immunology, Washington University School of Medicine,
St. Louis, Missouri, USA.

Macrophages (Mø) are integral in ischemia/reperfusion injury–incited (I/R-incited) acute kidney injury (AKI) that leads to
fibrosis and chronic kidney disease (CKD). IL-34 and CSF-1 share a receptor (c-FMS), and both cytokines mediate Mø survival
and proliferation but also have distinct features. CSF-1 is central to kidney repair and destruction. We tested the hypothesis
that IL-34–dependent, Mø-mediated mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD.
In renal I/R, the time-related magnitude of Mø-mediated AKI and subsequent CKD were markedly reduced in IL-34–deficient
mice compared with controls. IL-34, c-FMS, and a second IL-34 receptor, protein-tyrosine phosphatase ζ (PTP-ζ) were
upregulated in the kidney after I/R. IL-34 was generated by tubular epithelial cells (TECs) and promoted Mø-mediated TEC
destruction during AKI that worsened subsequent CKD via 2 distinct mechanisms: enhanced intrarenal Mø proliferation and
elevated BM myeloid cell proliferation, which increases circulating monocytes that are drawn into the kidney by chemokines.
CSF-1 expression in TECs did not compensate for IL-34 deficiency. In patients, kidney transplants subject to I/R expressed
IL-34, c-FMS, and PTP−ζ in TECs during AKI that increased with advancing injury. Moreover, IL-34 expression increased,
along with more enduring ischemia in donor kidneys. In conclusion, IL-34-dependent, Mø-mediated, CSF-1 nonredundant
mechanisms promote persistent ischemia-incited AKI that worsens subsequent CKD.

Introduction

Myeloid cells, most notably macrophages (Mø), regulate the
inflammatory response to injury. Mø are integral in ischemia/
reperfusion injury–incited (I/R-incited) acute kidney injury
(AKI) that resolves (1–3) or alternatively leads to chronic kidney
disease (CKD) (3). As Mø mediate kidney repair and destruction, we reasoned that the principal molecule required for Mø
survival, proliferation, and activation — CSF-1 — is central to
regulating the fate of the kidney. Our prior studies show that
CSF-1 expression is beneficial in kidneys destined to repair (4)
and, conversely, harmful in kidneys destined for autoimmunemediated chronic disease (3, 5–8).
CSF-1 functions by engaging a high-affinity RTK encoded
by the FMS proto-oncogene, the CSF-1R (c-FMS, also known
as CD115) (9, 10). c-FMS is principally expressed on mono
nuclear phagocytes, including progenitor cells (11), monoblasts, promonocytes, monocytes (12), Mø, and DCs (13). As
FMS null mice developed a more severe phenotype than mice
lacking CSF-1 (14), this finding led to the discovery of a second
c-FMS ligand, IL-34.
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IL-34 and CSF-1 have shared and differing properties. Both
cytokines promote the growth and survival of monocytes and formation of Mø colonies from BM (15). However, IL-34 is a dimeric
glycoprotein without sequence homology to the secreted glycoprotein CSF-1 isoform or any other known cytokine (16). Moreover, IL-34 and CSF-1 differ in spatiotemporal expression in some
adult and developing tissues (15), and they have partially overlapping c-FMS binding domains that may be responsible for dissimilar signal-activation kinetics (17). IL-34, but not CSF-1, is critical
in the maintenance of tissue-resident homeostatic Mø, such as
Langerhans cells and microglia (18). Moreover, while both IL-34
and CSF-1 signal through c-FMS, IL-34 has a second recently
uncovered receptor, PTP-ζ, at least in the brain (19). Although
CSF-1–mediated mechanisms during renal inflammation are well
documented by our laboratory and others (3, 5, 7, 8, 20–25), the
role of IL-34 in inflammation, particularly in the kidney, has not
been explored. The central issues are: (i) do IL-34–dependent,
Mø-mediated mechanisms augment or thwart AKI and subsequent CKD; (ii) are CSF-1 and IL-34 redundant during renal injury;
(iii) do IL-34–dependent, Mø-mediated mechanisms within and/
or outside the kidney alter renal injury; (iv) are IL-34–dependent
mechanisms responsible for shifting the dominant intrarenal Mø
phenotype prior to and/or after I/R; and (v) is intrarenal and systemic IL-34 expression relevant to ischemia-incited human AKI
and subsequent CKD? Taken together, we tested the hypothesis
that IL-34–dependent, Mø-mediated mechanisms promote persistent ischemia-incited AKI and the subsequent CKD.
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Figure 1. IL-34 is increased in the kidney after I/R. In each figure, expression is analyzed before and after I/R. (A) IL-34 expression in B6 TECs identified
using in situ hybridization (ISH), and CSF-1 using a CSF-1 reporter mouse (lacZ under control of Csf1 promoter and first intron) stained for β-galactosidase
activity (X-gal). Representative photomicrographs (n = 5). Original magnification, ×2.5; inset, ×20. Dotted lines indicate the junction between the cortex (C)
and the medulla (M). (B and C) We detected expression of intrarenal IL-34 transcripts and protein using qPCR (n = 5/group) (B) and ELISA (n = 4–11/group)
(C), respectively. (D) Il34 transcripts in the cortex and medulla were evaluated using qPCR (n = 5/group). *P < 0.01, **P < 0.001. Statistics analyzed using
the Mann-Whitney U test. Values are means ± SEM.

Results

Renal ischemic injury incites robust expression of IL-34 and CSF-1 in
tubules. Tubules, most notably in the outer medulla, are sensitive
to ischemic injury (26). Moreover, the interstitial areas adjacent to
ischemic-injured tubules are rich in Mø that often surround and
adhere to tubular epithelial cells (TECs) (3). Since IL-34 binds
to receptors on Mø and promotes Mø proliferation, we hypothesized that IL-34 is expressed by tubules following ischemic injury.
To test this hypothesis, we probed for the locale and magnitude
of IL-34 expression in the renal medulla and cortex of B6 mice
prior to and after I/R. Using in situ hybridization, we localized
ischemia-incited IL-34 expression to tubules (proximal, distal,
and collecting ducts) (Figure 1A). We verified this finding using
heterozygous IL-34–knockin mice (Il34LacZ/+) in which the IL-34
coding region was replaced by the gene coding β-galactosidase
(data not shown) (18). By comparison, CSF-1 — evaluated using
CSF-1 reporter mice expressing β-galactosidase — and IL-34 are
similarly expressed, as both c-FMS ligands are more abundant
in the medulla than in the cortex after I/R (Figure 1A). However,
while some TECs express both IL-34 and CSF-1 protein (immunostaining), other adjacent TECs express either IL-34 or CSF-1
in inflamed human kidneys (lupus nephritis, data not shown).
Moreover, IL-34 transcripts (Figure 1B) and protein (Figure 1C)
are robustly expressed after I/R. IL-34 expression rises rapidly
during the acute phase (d3, d5) and remains elevated during the
chronic phase (d20) (Figure 1, B and C) after I/R. As above, Il34
transcripts are more pronounced in the medulla than cortex (Fig-

ure 1D). By comparison, intrarenal Il34 transcripts and protein are
barely expressed prior to I/R (Figure 1, B and C). Il34 –/– kidneys
served as negative controls (Figure 1, B and C). Thus, IL-34 and
CSF-1 expression is abundant in renal tubules, but not necessarily
the same TECs, after I/R.
Overlapping and distinct expression of intrarenal IL-34 receptors after I/R. IL-34 and CSF-1 are ligands for c-FMS, a receptor
expressed on Mø and some other hematopoietic and parenchymal cells. However, unlike CSF-1, IL-34 binds to a second functional receptor, PTP-ζ, recently identified in mouse brain. We
examined the temporal response of Fms and Ptprz1 after I/R
using quantitative PCR (qPCR). Intrarenal Fms is expressed in
the acute phase (d3, d5) and increases during the chronic phase
(d20) after I/R (Figure 2A). We now report the finding that PTP-ζ
transcripts (Figure 2B) and protein (Figure 2C) are expressed
in the inflamed mouse kidney, albeit less robustly than in brain
(data not shown). Moreover, ischemia-induced IL-34 binds to
PTP-ζ in the kidney at d20 after I/R (Figure 2D). By comparison, Fms is more abundantly expressed than Ptprz1 during AKI,
while both are robustly increased during the chronic phase
after I/R (Figure 2, A and B). Using immunostaining, we found
PTP-ζ is expressed primarily by TECs and, to a lesser extent, by
cells in the inflamed interstitium after I/R (Supplemental Figure 1A; supplemental material available online with this article;
doi:10.1172/JCI81166DS1). We verified staining specificity using
an isotype control and by titration analysis. To further verify that
PTP-ζ is expressed by TECs, we stimulated primary cultured
jci.org   Volume 125   Number 8   August 2015
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Figure 2. IL-34 receptors have
overlapping and distinct
expression in the kidney after
I/R and IL-34 binds to PTP-ζ.
(A–B) Intrarenal Fms (A) and
Ptprz1 (B) transcript expression
on the same samples using
qPCR (repeated 3×). Statistics
analyzed using the Mann-Whitney U test. *P ≤ 0.05, **P ≤ 0.01.
Values are means ± SEM. (C).
Intrarenal PTP-ζ protein levels
detected by immunoblotting.
Quantitation of PTP-ζ relative
to GAPDH (n = 4). Statistics
analyzed using unpaired t test
(Mann-Whitney U test).
*P < 0.03. Values are means ±
SEM. (D) Immunoprecipitation
performed from kidney lysates
with PTP-ζ or control (mouse
IgG) Ab showing IL-34 binding
to PTP-ζ (n = 3).

TECs with either TNFα or IL-34 and analyzed Ptprz1 expression
using qPCR. Ptprz1 transcripts are upregulated in response to
either stimulus (Supplemental Figure 1B). While Mø ubiquitously
expressed c-FMS, it is unlikely that intrarenal Mø express PTP-ζ,
as WT BM-derived Mø (BMMø) polarized toward M1 and M2
phenotypes, representing opposite ends of the activation spectrum, do not express PTP-ζ in vitro. (Supplemental Figure 1C).
Thus, intrarenal c-FMS and PTP-ζ have overlapping and distinct
expression after I/R.
IL-34 mediates loss of tubules evident by the chronic phase after
I/R. To determine if IL-34 is central to promoting renal disease,
we compared pathology in Il34 –/– and WT mice in AKI and subsequent CKD after I/R (Figure 3A). Kidney weight and size is more
dramatically decreased in WT mice compared with Il34 –/– mice
at d20 and d37 after I/R (Figure 3B). As escalating inflammation
drives renal injury, we hypothesized that ischemia-incited renal
tubule IL-34 expression promotes leukocyte accumulation in the
interstitium, leading to tubule destruction. We detected more
tubular pathology (atrophy) and leukocytes in the interstitium in
WT compared with Il34 –/– mice after I/R (Figure 3C). To more fully
compare the loss of tubules in Il34 –/– and WT mice after I/R, we
used lotus tetragonolobus lectin (LTL) to detect proximal tubules
and dolichos biflorus agglutinin (DBA) to detect collecting ducts.
By the chronic phase after I/R, there are far fewer LTL+ and DBA+
cells in WT compared with Il34 –/– kidneys (d37, Figure 3D). Similar
findings appeared at d20 (data not shown). Thus, ischemia-incited
IL-34–dependent mechanisms mediate loss of tubules evident
during the chronic phase after I/R.
IL-34 mediates tubular injury during AKI. To determine
if intrarenal IL-34 fosters acute tubule injury leading to the
chronic loss of tubules, we compared the expression of kidney
3200
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injury molecule 1 (KIM-1) in WT and Il34 –/– mice after I/R. KIM-1
protein (Figure 4A) and transcripts (data not shown) are more
robustly expressed in WT compared with Il34 –/– TECs during
the acute phase after I/R. This suggests that IL-34 expression is
central to the initiation of tubule injury. Consistent with IL-34
driving AKI that is reflected in subsequent CKD, serum levels
of neutrophil gelatinase–associated lipocalin (NGAL), a reliable
marker of AKI progressing to CKD (27) (Figure 4B), and albuminuria (Figure 4C) are higher in WT compared with Il34 –/– mice
at d3 and d20 after I/R. Moreover, we detected more renal fibrosis in WT compared with Il34 –/– mice during the chronic phase
after I/R. Collagen protein was detected using Picrosirius red
staining (Figure 4D), and collagen 1 transcripts were detected
using qPCR (data not shown). Thus, ischemia-incited IL-34
mediates leukocyte-rich inflammation and tubule injury during
AKI and subsequent worsening of CKD.
IL-34 promotes intrarenal myeloid cell accumulation after renal
ischemic injury. Because myeloid cells, and in particular Mø,
are integral to renal ischemic injury and repair (3), we hypothesized that IL-34 promotes myeloid-mediated renal injury. As
anticipated, the accumulation of intrarenal neutrophils (Ly6G+)
precedes Mø (F4/80+), and declines rapidly as Mø ascend
and remain prominent in WT mice after I/R (Figure 5A). We
detected more intrarenal neutrophils and Mø in WT compared
with Il34 –/– during the acute and chronic phase after I/R (Figure
5A). Consistent with the enhanced magnitude of IL-34 expression, neutrophil and Mø accumulation was more abundant in
the medulla than cortex (Figure 5A). To identify the intrarenal
leukocyte populations in ischemia-incited renal injury, we used
flow cytometry (Figure 5B). We verified that fewer intrarenal
myeloid cells (CD45+CD11b+) are in Il34 –/– compared with WT
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Figure 3. Tubular atrophy and interstitial infiltration are diminished in Il34–/– after I/R. (A) Scheme: Time-related comparison for AKI and CKD after I/R.
(B) Representative kidneys from Il34–/– and WT B6 mice (left panel) and change in kidney weights (contralateral minus I/R kidney; right panel) after I/R
(n = 4–6/group). (C) Graphs indicate tubular atrophy and interstitial infiltration grades after I/R injury. Representative photomicrographs after I/R. Original
magnification, ×40. T, Tubule (n = 6–8/group). (D) LTL identifies proximal tubules, and DBA identifies collecting ducts after I/R. Graphs and representative
photomicrographs after I/R. Original magnification, ×10 (n = 6/group). Statistics analyzed using the Mann-Whitney U test. *P < 0.05,
**P < 0.01. Values are means ± SEM.

mice after I/R (Figure 5C). The decline in intrarenal myeloid
cells in Il34 –/– mice is initially due to a reduction in neutrophils
(CD45+Ly6G+CD11b+) (Figure 5D) and later results from fewer
Mø (CD45+CD11b+Ly6G –F4/80+) (Figure 5E). Thus, ischemia-
incited IL-34 expression mediates neutrophil and Mø accumulation in inflamed kidneys.
Renal ischemia incites IL-34 expression that promotes intrarenal
Mø proliferation. Mø, but not neutrophils, express the CSF-1 and
IL-34 receptor (c-FMS). Thus, signaling through c-FMS on Mø
may be responsible for intrarenal Mø accumulation after I/R. We
tested the hypothesis that ischemia-incited IL-34 expression in
TEC promotes intrarenal Mø proliferation. To test this hypothesis, we used 2 complementary in vivo proliferation assays: in situ
immunostaining (Ki67) and flow cytometry (5′-Bromo-2-deoxy
uridine [BrdU]). We detected more intrarenal proliferating Mø
(Ki67+F4/80+ cells) in WT compared with Il34 –/– mice during the
acute phase (d3, d5) and chronic phase (d20) after I/R (Figure
6A). Similarly, intrarenal BrdU+ myeloid cells (CD45+CD11b+),
and more specifically Mø (CD45+CD11b+Ly6G–), are far more
abundant in WT compared with Il34 –/– mice during the acute and
chronic phases after I/R (Figure 6B). The frequency of BrdU+
neutrophils remained low throughout the experiment (data not
shown). Thus, ischemia-incited IL-34 expression drives intrarenal
Mø proliferation.

To determine if IL-34 generated from ischemic TECs directly
fosters Mø proliferation, we used several in vitro approaches. We
compared Mø (WT BMMø) proliferation after stimulation with
supernatant from primary cultured hypoxic Il34–/– and WT TECs
(Figure 7A). We detected greater Mø proliferation after stimulation with hypoxic WT compared with Il34 –/– TEC supernatants, as
assessed by the MTT assay (Figure 7B). Therefore, hypoxia-incited
IL-34 expression by TECs enhances Mø proliferation. Mø stimulated with media alone or containing 20% L929 supernatant plus
10% FCS served as negative and positive controls, respectively.
Note, we did not detect a difference in viability of hypoxic WT and
Il34–/– TECs or normoxic WT and Il34–/– TECs, using trypan blue
exclusion and propidium iodide (PI) staining (Supplemental Figure 2A). Thus, Mø-stimulating supernatants are generated from
equivalent numbers of TECs. As the MTT assay is an index of both
proliferation and viability, to verify our proliferation findings, we
repeated the above experiment using BrdU incorporation in place
of MTT. Similarly, the number of BrdU+ Mø rises after stimulation with hypoxic compared with normoxic WT TEC supernatant
(Supplemental Figure 2B). Moreover, decreasing the concentration
of hypoxic supernatant reduces the magnitude of BrdU+ Mø (Supplemental Figure 2B). We verified that IL-34 in TEC supernatant
enhances Mø proliferation by adding recombinant IL-34 (rIL-34) to
the stimulating hypoxic Il34 –/– TEC supernatant. Adding increasing
jci.org   Volume 125   Number 8   August 2015
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Figure 4. KIM-1 expression and intrarenal fibrosis are decreased in Il34–/– after I/R. (A) KIM-1 expression (red) immunofluorescence after I/R. Graphs
(KIM-1/HPF) and representative photomicrographs. Nuclei are stained with DAPI (blue). Original magnification, ×20 (n = 6–8/group). (B) Serum NGAL levels evaluated by Luminex technology. (C) Urine albumin excretion over 8 hours evaluated by SDS-PAGE after I/R (n = 3–17/group). (D) Renal fibrosis using
collagen staining (Picrosirius red). Graphs (% Picrosirius red) and representative photomicrographs after I/R. Original magnification, ×10 (n = 6–8/group).
Statistics analyzed using the Mann-Whitney U test. *P < 0.05, **P < 0.01. Values are means ± SEM.

concentrations of rIL-34 restores Mø proliferation, in a step-wise
manner, to WT levels and beyond (MTT assay, Figure 7C). Thus,
IL-34 released from hypoxic TEC directly induces Mø proliferation.
Are IL-34 and CSF-1 released into the supernatant of hypoxic
TECs both responsible for driving Mø proliferation? IL-34 and
CSF-1 (protein) are upregulated in the supernatant of hypoxic WT
TEC (Figure 7E). Anti–IL-34 (neutralizing) Ab blockade of IL-34 in
supernatants from hypoxic WT TECs partially reduces Mø proliferation (Figure 7D). Similarly, substituting anti–CSF-1 Ab in place
of anti–IL-34 Ab also partially reduces Mø proliferation. Moreover, Mø proliferation is reduced to baseline (media alone) levels
by blocking CSF-1 in Il34 –/– hypoxic TEC supernatants (Figure 7D)
and by blocking CSF-1 together with IL-34 (using increasing concentrations of Abs) in WT hypoxic TEC supernatants (Supplemental Figure 2C). Thus, hypoxic TEC release IL-34 and CSF-1, which
additively are responsible for driving Mø proliferation.
Does CSF-1 compensate for the absence of IL-34 in the
ischemic kidney? We found that CSF-1 protein does not increase
in the supernatant of either hypoxic or TNFα-stimulated Il34 –/–
compared with WT TECs (Figure 7F). We found similar results
analyzing CSF-1 protein in TNFα-stimulated TEC homogenates
from Il34 –/– compared with WT mice (data not shown). This is
consistent with equivalent expression of Csf1 transcripts in TNFαstimulated Il34 –/– compared with WT TECs (Supplemental Figure
2D). Thus, CSF-1 does not compensate for the absence of IL-34 in
ischemic-injured TECs.
IL-34 stimulates BM myeloid cell proliferation and elevates circulating myeloid cells that are recruited to the kidney after I/R. Intrarenal IL-34 proliferation alone may not account for all IL-34–dependent Mø accumulation in the kidney. In this regard, we detected
3202
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an elevation of circulating IL-34 after I/R (Figure 8A). Moreover,
IL-34 contributes to myeloid cell development and thereby may
increase circulating monocytes (15). Therefore, we tested the
hypothesis that elevated systemic IL-34 increases the number of
circulating myeloid cells that are recruited to the kidney. Using
flow cytometry (Figure 8B), we detected an increase in myeloid
cells (Figure 8C), neutrophils (Ly6G+Ly6Cint, Figure 8D), and
inflammatory/migratory monocytes (CD45+CD11b+Ly6G–Ly6Chi,
Figure 8E) in circulation during the acute phase after I/R. Thus,
IL-34 promotes an increase of circulating neutrophils and monocytes during ischemia-incited AKI.
To determine whether systemic IL-34 promotes the rise in circulating myeloid cells, we tested the hypothesis that IL-34 mediates myeloid cell proliferation in the BM that subsequently enters
the circulation. To test this hypothesis, we analyzed myeloid cell
BrdU incorporation in BM, blood, and kidney before and after I/R
(Figure 8F). BrdU+ BM myeloid progenitor cells (SSCloCD45+CD11b+Ly6G–) are increased in WT compared with Il34 –/– mice during
the acute phase after I/R (Figure 8F, BM). Moreover, we detected
elevated circulating BrdU+ myeloid cells in WT compared with
Il34 –/– BM during the acute phase after I/R (Figure 8F, Circulation,
left). The increase in circulating myeloid cells results from a rise in
both neutrophils (Figure 8F, Circulation, middle) and monocytes
(Figure 8F, Circulation, right) in WT compared with Il34 –/– mice.
Thus, IL-34 promotes BM myeloid progenitor proliferation, leading to a rise of circulating monocytes and neutrophils after I/R.
To explore whether a rise in myeloid cells in the circulation
leads to a greater abundance of myeloid cells in the kidney, we
adoptively transferred equal numbers of CSF-1 receptor–labeled
BM cells (eGFP+ BM cells) into Il34 –/– and WT mice (3 hours prior
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Figure 5. Fewer Mø and neutrophils in Il34–/– compared
with WT kidneys after I/R. (A)
Neutrophils (Ly6G+/HPF) and
Mø (F4/80+/HPF) in the cortex
and medulla identified using
immunostaining. Representative
photomicrographs. Original magnification, ×10 (n = 4–6/group).
(B) Scheme depicting cell-sorting
approach. (C–E) Myeloid cell
(C), neutrophil (D), and Mø (E)
analysis by flow cytometry from
the whole kidney (n = 4–6/group).
Graphs and representative plots.
Statistics analyzed using the
Mann-Whitney U test. *P < 0.05,
**P < 0.01, ***P < 0.001. Values
are means ± SEM.

to sacrifice) after I/R. We found similar eGFP+ BM cells in the
circulation, but we found more eGFP+ cells in the kidney in WT
than Il34 –/– mice (Figure 9A). Thus, IL-34 mediates the number of
eGFP+ (myeloid cells) recruited to the inflamed kidney. Moreover,
we followed the same protocol but injected half the number of
eGFP-labeled BM cells into Il34 –/– mice. We found that the number of labeled cells injected into the circulation is proportional to
the number in the kidney (Figure 9A). Thus, increasing myeloid
cells in the circulation leads to more myeloid cell trafficking into
the inflamed kidney.

IL-34 mediates a rise in intrarenal chemokines that recruit monocytes to the inflamed kidney. Is IL-34 directly or indirectly responsible for enhancing monocyte recruitment to the kidney? To test
whether IL-34 directly recruits myeloid cells, we used a transwell
system; the upper and lower chambers are separated by a porous
membrane (Figure 9B). We determined whether stimulated TECs
expressing IL-34 (lower chamber) recruits WT BMMø (upper chamber). To avoid IL-34–mediated Mø proliferation (18- to 22-hour
turnover rate) (28), we examined recruitment at 3 hours and 6
hours after BMMø are seeded into the upper chamber. Blocking
jci.org   Volume 125   Number 8   August 2015
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Figure 6. IL-34 expressed by TECs promotes Mø proliferation. In vivo Mø Proliferation: (A) Paraffin sections dual-stained with anti-Ki67 (red) and
anti-F4/80 (green) Ab to identify proliferating Mø after I/R (n = 4–10/group). Dashed white lines outline tubules, and white arrows indicate Ki67-positive
nuclei. Representative photomicrographs and corresponding graphs (Ki67+F4/80+ cells/HPF). Original magnification, ×20. (B) Proliferating myeloid cells
and Mø are identified by BrdU staining and analyzed using flow cytometry (n = 3–6/group). Statistics analyzed using the Mann-Whitney U test. *P < 0.05,
**P < 0.01, ***P < 0.001, #P < 0.07, †P < 0.09. Values are means ± SEM.

MCP-1, a well-established Mø chemoattractant, reduced BMMø
migration at 6 hours (Figure 9B) and 3 hours (data not shown) after
BMMø are seeded into the upper chamber in a dose-responsive
manner. In contrast, blocking IL-34 did not alter BMMø migration
at 6 hours (Figure 9B) and 3 hours (data not shown) using the same
dose range as for MCP-1. This suggests that IL-34 generated by
TECs is not directly responsible for Mø recruitment.
We next tested the hypothesis that IL-34 indirectly recruits myeloid cells by increasing intrarenal chemokines. We detected more
intrarenal chemokines (MCP-1, also known as CCL2; MIP-1α, also
known as CCL3; and CX3CL1, also known as fractalkine), known
to recruit Mø, in WT compared with Il34–/– after I/R (Figure 10A).
The elevation in chemokines is not limited to those recruiting Mø, as
intrarenal IP-10, also known as CXCL10, (recruits T cells) is increased
and T cells are more abundant in WT compared with Il34–/– mice at d5
and d20 after I/R (Figure 10A and Supplemental Figure 3).
To determine whether IL-34 directly stimulates intrarenal
chemokine expression, we stimulated TECs with mouse IL-34 in
vitro. Stimulating TEC with TNFα (25 ng/ml) readily amplifies
chemokine expression (Figure 10B). In contrast, stimulating TECs
with varying doses of IL-34 (up to 10 times more than TNFα) does
not induce chemokine expression (Figure 10B). This suggests that
IL-34 does not directly induce chemokine expression in TECs.
To determine whether chemokines are primarily responsible
for recruiting Mø into the inflamed kidney, we blocked G protein–
coupled signaling, which blocks chemokine receptors, in BM cells
3204
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from MacGreen mice (eGFP reporter for c-FMS). For this purpose,
we incubated MacGreen BM cells with pertussis toxin (PTx) prior
to injecting these cells into WT mice after I/R (d1) (Figure 10C).
MacGreen BM cells incubated with heat-inactivated PTx served
as a negative control. The viability of MacGreen BM cells treated
with PTx or heat-inactivated PTx is 98 %–99% (PI staining, data
not shown). Blocking G protein–coupled signaling in eGFP+ WT
BM cells nearly eliminates all recruitment of these cells into the
inflamed kidney (Figure 10C). Taken together, IL-34 mediates
the proliferation of BM cells that, in turn, enter the circulation,
thereby increasing circulating myeloid cells that are recruited to
the inflamed kidney. Moreover, our data suggest that IL-34 indirectly mediates a rise in intrarenal chemokines that recruits myeloid cells into the kidney after I/R. In conclusion, both intrarenal
and systemic mechanisms regulate IL-34–dependent accumulation of myeloid cells in the inflamed kidney.
The processes of maintaining kidney-resident Mø and skewing
intrarenal-incited Mø phenotypes after ischemia are not dependent on
IL-34. Tissue-resident Mø (Ly6C –) are seeded during early development and maintained locally through homeostatic proliferation,
independent of monocytes. By comparison, Mø (Ly6C+) derived
from monocytes are recruited into inflamed tissues, where they
multiply and exert cyto-destructive or cyto-protective functions
(28). Recent studies indicate that IL-34 is required to maintain
homeostatic cyto-protective tissue-resident Mø (Ly6C–) in some
tissues, such as the brain and skin (18, 29). Thus, we determined
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Figure 7. IL-34 generated from hypoxic TECs directly induces Mø proliferation. In vitro Mø proliferation: (A) Scheme. (B) Cultured WT BMMø stimulated
(24 hours) with supernatants of Il34–/– and WT TECs after hypoxia or normoxic (24 hours) (MTT assay) (n = 3–4/group). (C) To rescue IL-34 in Il34–/– TEC
supernatant, rIL-34 is added to TEC supernatant prior to stimulating WT BMMø (MTT assay) (n = 3/group). (D) To block IL-34 or CSF-1 in WT TEC supernatant, anti–IL-34 or anti–CSF-1 Ab, respectively, are added to the TEC supernatant prior to stimulating WT BMMø (n = 3–4/group). (E) IL-34 and CSF-1 protein in supernatant of hypoxic and normoxic (24 hours) TECs evaluated by ELISA (n = 3-5/group). Dotted line represents Il34–/– hypoxic supernatant control
(n = 2). (F) CSF-1 protein in the supernatant of TNFα (25 ng/ml) stimulated and hypoxic Il34–/– and WT TECs. CSF-1 control is serum from mice injected i.p.
with LPS (25 μg) (n = 3–5/group). Statistics analyzed using the Mann-Whitney U test. *P ≤ 0.05, **P < 0.01. Values are means ± SEM.

whether IL-34 is required for the maintenance of tissue-resident
Mø in the kidney. We detected equivalent numbers of Ly6C – Mø
(CD45+Ly6C–CD11b+Ly6G–F4/80+) in Il34 –/– compared with WT
kidneys (nonmanipulated) (Supplemental Figure 4C) and in the
circulation (Supplemental Figure 4B). Moreover, the absence of
IL-34 does not alter kidney development, as Il34 –/– and WT kidneys are the same size (kidney/body weight, Supplemental Figure
4A) and appear similar by histology (data not shown). Thus, IL-34
is not required for kidney-resident Mø homeostasis. Once in the
inflamed kidney, Ly6C – Mø may either reflect an expansion of tissue-resident Mø or invading monocytes that switch from Ly6C+ to
Ly6C –. We detect equivalent frequencies of Ly6C – and Ly6C+ Mø
in WT and Il34–/– kidneys, and we detect more Ly6C+ and Ly6C–
Mø in WT compared with Il34 –/– kidneys after I/R (Supplemental
Figure 4). While there are far more Ly6C– than Ly6C+ Mø in both
WT and Il34 –/– kidneys, it remains unclear whether this reflects
an expansion of tissue-resident or invading monocytes. Taken
together, IL-34 expression does not skew Mø toward either Ly6C+
or Ly6C– phenotype in the kidney prior to or after I/R.

Broadly, Mø responding to local signals are divided into
functional states at opposite ends of the activation spectrum
(referred to as M1 and M2). Simplistically, M1 Mø promote
injury, while M2 are reparative (30–32). We tested the hypothesis that an IL-34–dependent shift in Mø phenotypes promotes
AKI. We found a predominance of M1-like Mø (CD45+Ly6G –
F4/80+NOS-2+TNFα+) during the acute phase that shift to the
M2 (CD45+Ly6G –F4/80+Arginase-1+Dectin-1+CD206+) phenotype during the chronic phase in WT mice after I/R (Supplemental Figure 5). The predominance of M1-like Mø during
the acute phase and M2-like Mø (CD45+Ly6G –F4/80+Arginase-1+Dectin-1+CD206+) during the chronic phase is more
pronounced in WT compared with Il34 –/– mice. However,
IL-34 does not skew intrarenal Mø toward either an M1-like or
M2-like phenotype, as the frequency of these phenotypes are
similar in WT and Il34 –/– mice after I/R (Supplemental Figure 5).
Thus, IL-34 expression does not shift intrarenal Mø phenotypes
toward either an M1 or M2 phenotype, but rather expands the
accumulation of Mø phenotypes.
jci.org   Volume 125   Number 8   August 2015
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Figure 8. IL-34 promotes myeloid cell proliferation in BM and increases circulating monocyte. (A) IL-34 protein in the circulation of WT mice after I/R
measured using an ELISA (n = 3–6/group). The serum collected 6 hours after LPS injection (25 μg, i.p.) into WT mice is used as a positive control, and
serum from Il34–/– mice (dashed line) is used as a negative control (n = 14). (B–E) Scheme (B), graphs, and plots using flow cytometry analysis to evaluate
the frequency of myeloid cells (C), neutrophils (D), and monocytes (E) in the circulation after I/R (n = 4–10/group). (F) Scheme. BrdU (2 mg) was injected 3
hours prior to sacrifice. Data was analyzed using flow cytometry. BM: Proliferating SSClo myeloid cells in BM. Circulation: Proliferating circulating myeloid
cells, Ly6Chi neutrophils and monocytes mice (n = 3–6/group). Statistics analyzed using Mann-Whitney U test. *P < 0.05, **P < 0.01, #P ≤ 0.06, †P < 0.09.
Values are means ± SEM.

IL-34 and IL-34 receptors are upregulated in TECs after I/R in
human kidneys. IL-34 is upregulated in ischemia-incited human
inflamed kidneys. Because I/R injury is an inevitable consequence
of the kidney transplant procedure and prolonged ischemia leads
to poorer graft survival (33), we probed for IL-34 in the engrafted
and rejected kidney during the first 6 months after transplantation (acute phase) (Supplemental Table 1A). IL-34 is upregulated
in the engrafted kidney compared with the donor kidney (living
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and deceased after reperfusion) and rises even higher during
acute kidney rejection (Figure 11A). In mice, after I/R, IL-34 is
expressed predominately by TECs (Figure 1A), and IL-34 mediates the survival and proliferation of Mø and the accumulation of
neutrophils. Therefore, we tested the hypothesis that intrarenal
IL-34 expression promotes the accumulation of intrarenal myeloid cells. Consistent with the level of IL-34 expression in TECs,
we detected far more Mø (CD68+) and neutrophils (Ly6G+) in
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Figure 9. IL-34 recruits BM derived cells to the kidney by indirectly amplifying intrarenal chemokines after I/R. (A) Il34–/– and WT mice are intravenously
injected either with the same or half the number of BM cells from MacGreen mice 3 hours before sacrifice at d1 after I/R. Blood and kidney are collected
and analyzed by flow cytometry for the number and frequency of donor cells, respectively (n = 5–14/group). (B) Induction of BMMø migration to stimulated
TEC supernatants incubated with and without diluted anti–IL-34 and anti–MCP-1 Abs (n = 4/group), repeated 3×. Statistical differences are determined by
Mann-Whitney U test. *P < 0.05, **P < 0.01. Values are means ± SEM.

the renal interstitium in engrafted compared with donor kidneys
that are even more pronounced during kidney transplant rejection (Supplemental Figure 6). Note, Mø are far more abundant (2
times) than neutrophils in the transplanted kidneys. Thus, ischemic injury in human kidneys upregulates IL-34 in TECs and simultaneously increases renal interstitial Mø and neutrophils. Accompanying IL-34 expression by TECs, we detected a pronounced rise
in serum IL-34 during rejection compared with engraftment and
healthy controls (Figure 11B). IL-34 serum levels reflected intrarenal IL-34 expression, as serum and TEC-derived IL-34 correlate
with the magnitude of IL-34 expression in rejected and engrafted
kidney transplants (Figure 11C).
To further explore the relationship of I/R and IL-34 in patients,
we compared deceased donor kidney (more ischemic) with living
donor kidneys (less ischemic) prior to and after reperfusion (Supplemental Table 1B). IL-34 expression is higher in human deceased
and living donor kidneys after reperfusion compared with before
reperfusion (Figure 12A). Moreover, IL-34 expression is elevated
in deceased compared with living donor kidneys both before and
after reperfusion (Figure 12A). This suggests that intrarenal IL-34
expression rises with increasing renal ischemia in patients receiving a kidney transplant.
To determine whether the IL-34 receptors are upregulated
along with IL-34, we probed for PTP-ζ and c-FMS expression in the
same human kidney transplants (Figure 11A). PTP-ζ and c-FMS
expression are both upregulated in kidney transplants (Figure
11A). Moreover, PTP-ζ and c-FMS are expressed by TECs and in
some cells in the interstitium (Figure 11A). As PTP-ζ is more abun-

dant in the chronic compared with acute phase after I/R, we compared PTP-ζ in patients with acute and chronic kidney transplant
rejection. Similar to our findings in mice, PTP-ζ is more abundant
in chronic compared with acute kidney transplant rejection (Figure 12B). Since IL-34 and IL-34–receptor expression in mouse and
human kidneys are similarly upregulated within ischemia-incited
renal injury, and IL-34 promotes ischemia-incited AKI, we speculate that IL-34 mediates human renal injury.

Discussion

We report here the finding that IL-34 promotes Mø-mediated
persistent ischemia-incited AKI, worsening subsequent CKD.
IL-34 expression is upregulated in TECs during the acute phase
and remains elevated during the chronic phase after I/R, and it is
maximal in the medulla, the site most sensitive to I/R injury. By
comparison, the receptors for IL-34, c-FMS and PTP-ζ, are maximally expressed in the chronic phase after I/R. Intrarenal IL-34
promotes Mø-mediated TEC destruction during the acute and,
subsequently, the chronic phase after ischemic injury. Intrarenal
IL-34 fosters Mø accumulation via 2 distinct mechanisms: enhancing Mø proliferation locally in the kidney and releasing IL-34 into
the circulation, leading to a rise in BM myeloid cell proliferation
that subsequently enter the circulation and increase circulating
monocytes. The IL-34–dependent rise in circulating myeloid cells
provides a larger pool of myeloid cells available for recruitment to
the inflamed kidney. IL-34 does not directly recruit monocytes,
but rather increases intrarenal inflammation and thereby chemo
kines that draw circulating myeloid cells to the inflamed kidney.
jci.org   Volume 125   Number 8   August 2015
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Figure 10. IL-34 mediates a
rise in intrarenal chemokines
that recruit monocytes to the
inflamed kidney. (A) Kidneys are
analyzed for transcript expression of selected chemokines at
d3 after I/R using qPCR (n = 4–5/
group). (B) TECs after stimulation
with IL-34 and TNFα are analyzed
for transcript expression of
select chemokines (n = 4/group),
repeated 2×. (C) Recruitment
of myeloid cells tested as in A.
To inhibit G-coupled receptors,
donor cells are pretreated with
PTx (100 ng/ml, 1 hour). Control:
donor cells pretreated with
heat-inactivated PTx (n = 5–6/
group). Statistical differences are
determined by Mann-Whitney
U test. *P < 0.05, **P < 0.01.
Values are means ± SEM.

I/R injury is an inevitable consequence of the kidney transplantation procedure. We detected increased IL-34 expression by TECs
in human transplanted kidneys. Moreover, IL-34 is increased in
the serum of recipients with transplanted kidneys and rises higher
with advancing renal inflammation. CSF-1 does not compensate
for the absence of IL-34. Thus, targeting IL-34 is a potential therapeutic to suppress AKI and subsequent CKD. Further detailed
studies are required to determine whether targeting IL-34 during
the chronic phase after I/R alone suppresses CKD.
While IL-34 and CSF-1 share a common receptor and partially overlap in functions, the list of their distinct actions is rapidly expanding (34-37). The roles of IL-34 and CSF-1 clearly differ
during growth and development. For example, Csf1op/op mice lacking a functional CSF-1 express an obvious phenotype, including
reduced body and kidney size and weight, frailty, defective skeletal and tooth formation, and infertility (24, 38). By comparison,
other than the microscopically evident loss of Langerhans cells
and microglia (18, 29), Il34 –/– mice express a normal phenotype,
including normal body and kidney size and weight, and similar
numbers of circulating and intrarenal monocytes and neutrophils
compared with WT mice. The recent discovery of a second IL-34
receptor, PTP-ζ, in neural progenitor and glial cells in the brain
may be responsible for some differing functions of IL-34 and
CSF-1. Intrarenal PTP-ζ is expressed primarily by TEC and binds
to IL-34. Moreover, PTP-ζ is more robustly expressed during
the chronic compared with acute phase after ischemia-incited
renal injury. By comparison, intrarenal c-FMS expression is more
abundant than PTP-ζ during the acute phase, while both IL-34
receptors are maximally expressed during the chronic phase
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after I/R. PTP-ζ and c-FMS may be central to fibrosis, as these
transcripts rise along with the loss of tubules and replacement by
fibrosis. Moreover, IL-34 and CSF-1 are overexpressed in chronic
hepatitis C liver fibrosis and induce profibrotic Mø (39). Dissecting the role of PTP-ζ in kidney disease may be complex, as this
receptor binds to and signals through the actions of multiple ligands (40), including the heparin binding growth factors pleiotrophin and midkine (41), the cell surface protein contactin (42),
and the extracellular matrix protein tenascin-R (43). It will be
intriguing to pinpoint the PTP-ζ– and/or c-FMS–mediated IL-34–
dependent and –independent mechanisms that may be central to
intrarenal fibrosis.
IL-34 and CSF-1 are the principle molecules released from
TECs that mediate intrarenal Mø proliferation, as eliminating
both of these molecules, but not either alone, reduces Mø proliferation to baseline levels. Moreover, CSF-1 does not compensate for
the lack of IL-34 during inflammation, as ischemia-incited renal
injury is diminished in Il34 –/– compared with WT mice, and stimulated Il34 –/– and WT TEC express similar levels of CSF-1. This is
consistent with the absence of a compensatory increase in Il34
mRNA expression in Csf1op/op mice in several noninflamed tissues
(ear, skeletal muscle, liver, salivary gland, and spleen) (15). Moreover, elevated intrarenal IL-34 is not restricted to I/R injury. IL-34
protein and transcripts are abundantly upregulated in MRL-Faslpr
mice with spontaneous CKD (lupus nephritis, unpublished data),
and intrarenal Il34 transcripts are elevated in the kidney of other
models with lupus nephritis (44). These findings have seeded
studies to clarify whether IL-34 is a potential therapeutic target for
chronic kidney diseases with multiple etiologies.
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Figure 11. Intrarenal IL-34 is increased in engrafted and rejected kidney transplants. (A) Kidney biopsies include: the *donor (defined as donor biopsy
from living and deceased donors after reperfusion) and engrafted and rejected (acute cellular) transplant (within 6 months of transplant). IL-34, PTP-ζ, and
c-FMS expression detected in renal biopsy by immunostaining (brown reaction product) in TECs and interstitium. White arrows denote PTP-ζ–expressing
cells, and black arrows denote c-FMS–expressing cells. Representative photomicrographs. Original magnification, ×40 (n = 7–12/group). (B) Serum IL-34
expression in *donor and transplanted kidneys quantified by an ELISA (n = 17–84/group). (C) Correlation of serum and IL-34+ TEC expression (n = 7–10/
group). Demographic and patient clinical characteristics detailed in Supplemental Table 1. Statistics analyzed by the Mann-Whitney U test. *P < 0.05,
**P < 0.01, ***P < 0.001. Values are means ± SEM.

Are the actions of IL-34 and CSF-1 similar or distinct in ischemia-incited renal injury? While ischemia-induced IL-34 drives AKI
and thereby worsens subsequent CKD, our prior studies (4) and
others (24, 25) indicate that CSF-1 hastens AKI repair after I/R.
However, CSF-1 mediates repair in AKI and conversely escalates
spontaneous (MRL-Faslpr lupus nephritis) (3, 5, 7, 8, 20) and induced
(unilateral ureteral obstruction) (22, 23) CKD. This divergent role of
CSF-1 is analogous to epidermal growth-factor receptor signaling in
AKI and CKD. (45, 46). One caveat concerning the distinct actions
of IL-34 and CSF-1 in AKI relates to comparing differing models/
methods (CSF-1–transgenic, CSF-1–injected, and CSF-1–deficient
osteopetrotic Csf1op/op mice, versus Il34–/– mice) and experimental
I/R protocols. Nevertheless, our data support the concept that the
roles of IL-34 and CSF-1 are dissimilar in renal injury, a finding consistent with nonredundant features of these c-FMS ligands.
Unlike CSF-1, IL-34 does not directly recruit monocytes into the
inflamed kidney (7). Our data suggest that intrarenal IL-34 incites
inflammation and the expression of chemokines, such as MCP-1,

that recruit monocytes into the inflamed kidney (47). This is consistent with markedly weak IL-34–mediated direct migration of
the mouse monocyte/Mø cell line (J774A.1) in vitro (17). Moreover,
IL-34–dependent elevated intrarenal inflammation is a plausible
explanation for the rise in neutrophils in the circulation and kidney in WT compared with Il34 –/– mice (48). Taken together, IL-34
directly and indirectly mediates AKI, worsening subsequent CKD.
IL-34 fosters homeostatic, protective, tissue-resident Mø in
select tissues. Mø are divided according to their origin. Tissue-
resident Mø (Ly6C–) are seeded during early development; are
maintained locally through homeostatic proliferation, independent of monocytes; patrol peripheral tissues; and exert a broad
range of immunoregulatory, cyto-protective functions (28). By
comparison, monocyte-derived Mø (Ly6C+) are recruited into
inflamed tissues, where they multiply and exert cyto-destructive or
cyto-protective functions (28). Initial in vitro evidence suggested
that IL-34 promotes the expansion of cyto-protective Mø in tissues,
as IL-34–stimulated Mø express an immunosuppressive cytokine
jci.org   Volume 125   Number 8   August 2015
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Figure 12. IL-34 is upregulated in reperfused deceased donor kidneys, and PTP-ζ is more abundantly expressed in chronic than acute transplant rejected
kidneys. (A) IL-34 expression in living and deceased donor biopsies before and after reperfusion (n = 7/group). (B) PTP-ζ expression in acute and chronic
disease in human kidney transplants (n = 7/group). Graph and representative photomicrographs. Original magnification, ×40. Demographic and patient
clinical characteristics detailed in Supplemental Table 1. Statistics analyzed by the Mann-Whitney U test. *P < 0.05. Values are means ± SEM.

profile (IL-10hi, IL-12lo), reduce Mø mediated T cell stimulation and
proliferation, and skew human monocytes toward a M2 phenotype
(49). Moreover, IL-34 is required for the maintenance of homeostatic cyto-protective tissue-resident Mø (Ly6C–) in brain and skin
(18, 29). We now report that IL-34 does not maintain kidney-resident Mø, as the number and frequency of Ly6C– is similar in nonmanipulated Il34 –/– and WT kidneys. Thus, IL-34 is not required to
maintain homeostatic cyto-protective Mø in the resting kidney.
IL-34 mediates intrarenal Mø accumulation but does not shift
phenotypes during AKI and subsequent CKD. Several previous
studies indicate that M1-like Mø drive injury and M2-like Mø mediate repair during renal inflammation (1, 3, 25). Our findings are
consistent with a rise in IL-34–dependent M1-like Mø mediating
more severe AKI. Although the abundance of M2-like Mø in ischemia-incited CKD is seemingly at odds with some prior studies in
renal inflammation, there are possible explanations. Growing evidence shows M2-like Mø are the dominant phenotype in fibrotic
lesions of CKD of many etiologies. For example, the abundance
of M2-like Mø in human and mouse polycystic kidney disease
(PKD), contribute to the progression of renal disease by promoting
cyst growth and fibrosis (50). Similarly, M2-like Mø proliferation
and infiltration is associated with tubular injury and progression
of fibrosis during inflammation in human kidney transplant allo
grafts (51, 52). Moreover, insufficient renal epithelial healing in
mice promotes an expansion of M2-like Mø that accelerates fibrogenesis (reviewed in ref. 53). These findings in kidney disease are
in keeping with the profibrotic functions of M2-like Mø in the liver
(54). As we find a predominance of M2-like Mø–expressing markers (CD 206+, Arginase-1+, Dectin-1+) linked to fibrosis (55–57)
in fibrotic kidneys after I/R, our findings are consistent with the
concept that these intrarenal Mø are profibrotic. Since fibrosis is a
protective response to tissue injury, M2-like Mø may mediate both
repair and fibrosis. Moreover, when renal injury is severe, as in our
study, fibrosis results in substantial loss of tissue and CKD. Thus,
it is not inconsistent that some have found intrarenal M2-like Mø
during renal repair, while we found M2-like Mø in fibrotic kidneys during CKD. To add to the complexity of defining the roles
of M2-like Mø, activated Mø phenotypes extend far beyond the
simplistic M1 and M2 paradigm, making it challenging to compare
Mø phenotypes and functions in differing experimental settings,
even within the kidney. In conclusion, our findings show IL-34
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increases intrarenal Mø but does not skew the Mø phenotype
(within the context of the M1 and M2 markers we explored) during
AKI and subsequent CKD.
We wish to highlight the finding that IL-34 and IL-34 receptors
are upregulated in ischemia-incited human inflamed kidneys. As
IL-34 and IL-34–receptor expression in mouse and human kidneys
are similarly upregulated, we speculate that IL-34 in transplanted
kidneys may mediate rejection and other forms of renal injury. In
conclusion, our mouse experimental data and human data suggest
that targeting IL-34 in the kidney and circulation is likely a potential therapeutic strategy to suppress AKI and subsequent CKD.

Methods

Mice. We purchased C57Bl/6 (B6) mice from The Jackson Laboratory
and Harlan. Transgenic Tg(Fms-EGFP) mice that express eGFP under
the control of Fms promoter and first intron (MacGreen), were provided by D. Hume (Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom). We backcrossed MacGreen mice onto the
B6 background (MacGreen;B6) (4, 23). To generate IL-34 null LacZ+
(Il34 –/–;B6) mice, B6 mice were deleted of Il34 exons 3–5 and intercrossed with Il34LacZ/+ offspring, as previously described (18). Transgenic mice expressing lacZ under the control of Csf1 promoter and the
first intron (TgN9[Csf1-Z]Ers7/+) (58) were provided by E.R. Stanley
(Albert Einstein College of Medicine, New York, New York, USA) and
backcrossed to B6 in our facility at Harvard Medical School, Boston,
Massachusetts, USA. IL-34 is required for the development of Langerhans cells (18); thus, in addition to using PCR to detect the deletion of
Il34, we probed for the loss of Langerhans cells in the epidermis of the
ear (59). All breeding housing and colony housing was done at Harvard Medical School.
I/R. We anesthetized female mice (6 weeks of age) and exposed
the left kidney through a flank incision. We induced ischemia by
clamping the renal pedicle with nontraumatic microaneurysm clamps
(Roboz Surgical Instrument Co.). Clamps were removed after 45 minutes. Body temperature was controlled at 36.8°C–37.2°C throughout
the procedure.
In situ hybridization. The digoxigenin-labeled (DIG-labeled) antisense oligonucleotide probe for mouse IL-34 was synthesized by in
vitro transcription using T7 RNA polymerase and Dig Labeling Mix
(Roche Applied Science) from cDNA template amplified from plasmid
IL-34–pBS-SK (a gift from E.R. Stanley), and purified with Micro Bio-
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Spin 30 Columns (Bio-Rad). Kidneys were fixed in 4% paraformaldehyde overnight, immersed in 30% sucrose/PBS overnight at 4°C, and
then embedded and cryostat-sectioned at 20 μm. The kidney sections
were prepared and processed for in situ hybridization, as previously
described (60). After development, slides were fixed in 4% PFA overnight and dried, and cover slips were mounted for imaging.
β-Galactosidase. β-Galactosidase staining was performed, as previously described (61). Kidneys were fixed in 4% paraformaldehyde
for 3 hours at 4°C, embedded and sectioned at 20-μm thick sections.
Cryosections were stained with X-gal (catalog X4281C10; Gold Biotechnology) overnight at 37°C and subsequently counterstained with
Nuclear Fast Red (catalog N3020; Sigma-Aldrich).
Immunoblotting. Kidney tissues were homogenized in RIPA buffer, and 25 μg total protein was used for immunoblotting, as previously
described (62). Blots were probed with mouse monoclonal PTP-ζ Ab
(3F8; Developmental Studies Hybridoma Bank, University of Iowa,
Iowa City, Iowa, USA). Mouse monoclonal anti-GAPDH Ab (catalog D16H11; Cell Signaling Technology) was used as loading control.
Images were captured using ChemiDoc MP imaging system (Bio-Rad).
Immunoprecipitation. We performed immunoprecipitation, as previously described (62). Briefly, kidney tissues were homogenized in
CHAPS buffer (30 mM Tris-Cl pH 7.5, 150 mM NaCl, 1% CHAPS containing protease and phosphatase inhibitor cocktails [Sigma-Aldrich])
and 250 μg total protein incubated with 1 μg of PTP-ζ Ab overnight
at 4°C. Proteins were transferred onto nitrocellulose membrane, and
immunoblotting was performed with polyclonal anti-sheep IL-34 Ab
against Asn21-Pro242 (catalog AF5265; R&D Systems). Mouse monoclonal anti-GAPDH, (catalog D16H11; Cell Signaling Technology) and
mouse heavy chain IgG were used as loading control for input and
immunoprecipitation, respectively.
Renal histopathology. Kidneys were fixed in 10% neutral buffered
formalin, embedded in paraffin, sectioned (4 μm), and stained with
periodic acid-Schiff (PAS). We scored kidney pathology, as previously
detailed (63).
Immunostaining. We stained cryostat-cut mouse kidney sections
for the presence of: Mø, using anti–mouse F4/80 Ab (clone BM-8;
Invitrogen) and anti–mouse CD68 Ab (clone FA-11; AbD Serotec), as
previously detailed (4); proximal tubules using fluorescein isothiocyanate–conjugated (FITC-conjugated) lotus tetragonolobus lectin
(LTL; Vector Laboratories) and collecting ducts using biotinylated dolichos biflorus agglutinin (DBA; Vector Laboratories) in combination
with Texas red streptavidin (Vector Laboratories); and neutrophils,
using anti–mouse Ly6G Ab (clone 1A8, BioLegend). To determine
the number of proliferating Mø, cryosections were stained with anti–
mouse F4/80 Ab (clone BM-8, Invitrogen), and anti–mouse Ki-67 Ab
(clone SP6, Vector Laboratories), followed by FITC-conjugated goat
anti-rat IgG Ab (Invitrogen) and Cy3-conjugated goat anti-rabbit IgG
Ab (Invitrogen). We enumerated the number of F4/80+/Ki-67+ cells in
20 high-power fields (HPF).
Kidney biopsy sections were incubated with a primary Ab, rabbit
anti–human IL-34 Ab (clone C-19, catalog sc-243072, Santa Cruz Biotechnology Inc.) rabbit anti–human PTP-ζ (catalog ab126497, Abcam),
rabbit anti–human CSF-1R (clone C-20, catalog sc-692, Santa Cruz
Biotechnology Inc.), rat anti–human Ly6G (clone RB6-8C5, catalog
ab25377, Abcam), and mouse anti–human CD68 (clone SPM130,
sc-52998, Santa Cruz Biotechnology Inc.). The primary Ab was detected
by incubating with biotinylated goat anti-rabbit Ab, rabbit anti-rat, and
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goat anti-mouse Ab, followed by development with 3-3-diaminobenzidine (Vector Laboratories), as previously detailed (4). Nonspecific
binding was determined using rabbit anti-human IgG (IL-34 staining)
or rat anti-human (Ly6G staining), or with mouse anti-human IgG
(CD68 staining) (eBioscience). We determined the percent-positive
TECs or positive infiltrating cells in 10 randomly selected HPFs.
Albuminuria. To quantify albuminuria levels, we analyzed 20 μl
urine collected over 8 hours by SDS-PAGE, as previously described (64).
Collagen detection. We stained paraffin sections after rehydration
in Picrosirius red solution for 1 hour and rinsed with acidified water.
After kidney sections were dehydrated and mounted, the magnitude of
staining was analyzed as previously detailed (4) using a Nikon Eclipse
E1000 upright fluorescence microscope and Adobe Photoshop CS2.
KIM-1 and NGAL expression. Kidney cryostat-cut sections were
stained with polyclonal anti–KIM-1 Ab to determine tubular injury, as
previously detailed (4). The NGAL protein was detected using a Luminex xMAP technology, as previously described (65).
Generating BMMø. Mø were generated from mouse BM, as previously detailed (3).
Stimulating Mø using hypoxic TEC supernatant. We isolated and
expanded TECs from Il34 –/– and WT kidneys, as previously reported
(3). We cultured TECs for 24 hours under hypoxic conditions with 99%
N2/1% O2 at 37°C in a hypoxic chamber and evaluated viability using
both microscopic analysis of trypan blue exclusion staining and flow
cytometry analysis of PI staining. Cell supernatant was collected after
hypoxia and was used to stimulate BMMø. To derive BMMø, we cultured BM in L929 conditioned media and then starved BMMø in serumfree DMEM medium without L929 for 2 hours. We incubated BMMø
with supernatant from hypoxic Il34 –/– and WT TECs. To restore IL-34
in Il34 –/– TEC supernatants, we added rIL-34 protein to hypoxic Il34 –/–
TEC supernatant at concentrations ranging from 50–500 ng/mL. To
block IL-34 and CSF-1, anti–IL-34 Ab (10 μg/ml, catalog AF5195, R&D
Systems) and anti–CSF-1 Abs (2 μg/ml, 552513, BD Biosciences) neutralizing Abs were added to hypoxic WT and Il34 –/– TEC supernatants
during incubation with BMMø. After incubating for 24 hours, we analyzed Mø proliferation with the MTT assay (Roche Diagnostics) and
BrdU incorporation (10 μM, 2 hours) using flow cytometry.
ELISA. To quantify IL-34 and CSF-1 levels, in the kidney, circulation and hypoxic and normoxic TEC supernatants, samples were
analyzed using a mouse IL-34 ELISA (R&D Systems) according to the
manufacturer’s instructions and a mouse CSF-1 ELISA (7). We measured human IL-34 levels with a human IL-34 ELISA (R&D Systems)
according to the manufacturer’s instructions. All measurements were
made in duplicate.
qPCR. qPCR was performed, as previously described (4). We
detected Csf1, Il34, Fms, Ptprz1 and Gapdh using QuantiTect Primer
Assays (QIAGEN) or using primers purchased from Invitrogen and
Integrated DNA Technologies: Csf1, forward 5′-GGCTTGGCTTGGGATGATTCT-3′, reverse 5′-GAGGGTCTGGCAGGTACTC-3′; Il34,
forward 5′-TTGCTGTAAACAAAGCCCCAT-3′, reverse 5′-CCGAGACAAAGGGTACACATTT-3′; Fms, forward 5′-TGTCATCGAGCCTAGTGGC-3′, reverse 5′-CGGGAgATTCAGGGTCCAAg-3′; and Gapdh,
forward 5′-AGGTCGGTGTGAACGGATTTG-3′, reverse 5′-TGTAGACCATGTAGTTGAGGTCA-3′. Other purchased primers used in this
study were: collagen I, forward 5′-TgACTGGAAGAGCGGAGAGT-3′,
reverse 5′-GTTCGGCTGATGTACCAgT-3′; fractalkine/Cx3cl1, forward 5′-TCGGACTTTGTTGGTTCCTC-3′, reverse 5′-CAAAATGGjci.org   Volume 125   Number 8   August 2015

3211

Downloaded from http://www.jci.org on December 11, 2015. http://dx.doi.org/10.1172/JCI81166

Research article

The Journal of Clinical Investigation  

CACAGACATTGG-3′; Kim1, forward 5′-TAAACCAGAGATTCCCACAC-3′, reverse 5′-GATCTTGTTGAAATAGTCGTG-3′; Mcp-1/Ccl2,
forward 5′-GCTTGAGGTGGTTGTGGAAAA-3′, reverse 5′-CTCACCTgCTgCTACTCATTC-3′; Mip1a/Ccl3, forward 5′-TCTCCACCACTGCCCTTgCT-3′, reverse 5′-GGCGTGGAATCTTCCGGCTGT-3′; and
Ptprz1, forward 5′-GGAGTATCCAACAGTTCAGAGGC-3′, reverse
5′-AAGTCAGGGCAGACACGATCAC-3′. Ip10/Cxcl10 expression was
examined using primers designed by Applied Biosystems. The data were
analyzed by the ΔΔ-CT method.
Flow cytometry. We prepared and stained single-cell suspensions
from kidneys, RBC-lysed BM, and blood cells for intracellular and
extracellular antigens as previously described (63).
Antibodies for flow cytometry. We used the following antibodies
from BioLegend for FACS analysis: FITC-conjugated anti–mouse/
human CD11b Ab (clone M1/70); phycoerythrin-conjugated (PE-conjugated) anti–mouse CD115 Ab (clone AFS98); FITC-conjugated anti–
mouse CD206 Ab (clone 15-2); PE-conjugated anti–mouse Ly6C Ab
(clone HK1.4); PE-conjugated anti–Dectin-1 Ab (clone RH1); PerCP/
Cy5.5-conjugated anti–mouse/human CD11b Ab (clone M1/70); allophycocyanin-conjugated (APC-conjugated) anti–mouse F4/80 Ab
(clone BM-8); pacific blue–conjugated anti–mouse CD45 Ab (clone
30-F11); APC/Cy7-conjugated anti–mouse Ly6G Ab (clone 1A8); biotinylated anti–mouse Ly6C Ab (clone HK1.4); FITC-conjugated TNFα
(clone MP6-XT22); and FITC-conjugated streptavidin. In addition,
we used FITC-conjugated anti–CD3ε (clone 145-2C11) Ab from eBioscience, FITC-conjugated anti–iNOS-2 (6/iNOS/NOS Type II) Ab
from BD Biosciences, and PE-conjugated anti–Arginase-1 polyclonal
Ab from R&D Systems.
BrdU incorporation assay. We injected mice (i.p.) with BrdU (2 mg/
mouse, Sigma-Aldrich) 3 hours before sacrifice. BrdU+ cells were analyzed with an anti-BrdU Ab (clone Bu20a, BioLegend) by flow cytometry.
Adoptive transfer. We isolated BM from MacGreen;B6 mice and
adoptively transferred the eGFP+ cells (2 × 107 and 1 × 107) by injection
into the tail vein of Il34 –/– and WT mice 24 hours after I/R. Mice were
sacrificed 3 hours later. Kidney and blood samples were processed to
detect eGFP+ cells using flow cytometry, as previously detailed (63).
Recruitment assays. BM (2 × 107) cells from MacGreen mice
(eGFP+ myeloid cells) were stimulated either with active or heat-
inactivated (95°C, 30 minutes) PTx, as previously described (66),
and adoptively transferred into WT B6 mice after I/R (d1). After
3 hours, kidneys and blood were collected and analyzed by flow
cytometry. The viability of donor cells was tested using PI (Sigma-
Aldrich) and analyzed by flow cytometry.
Chemotaxis assay. TECs isolated from B6 mice were incubated
with TNFα (25 ng/ml) with and without anti–IL-34 Ab (catalog AF5195,
R&D Systems) and anti–MCP-1 Ab (catalog 479-JE-010, R&D Systems)
using increasing concentrations (1.25–40 μg/ml). Following stimulation
for 24 hours, the supernatant was replaced and stimulated TECs were
coincubated with primary isolated Mø from B6 mice using a 2-chamber,
96-well plate separated by a polycarbonate membrane (pore size: 5 μg/
ml). To quantify Mø chemotaxis, samples were analyzed in duplicate
according to the manufacturer’s instructions (Cell Biolabs Inc.).
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Serum and renal biopsy specimens. The demographic and clinical
characteristics for the cohort used in this study are listed in Supplemental Table 1, A and B. Human kidney sections from transplanted
kidney biopsies and donor biopsies prior to transplantation were provided by the Department of Pathology, Friedrich-Alexander University of Erlangen-Nuernberg, Erlangen, Germany. Donor-kidney biopsies from living and deceased donors were evaluated before and after
reperfusion. The following criteria were used to define these patient
biopsies: living donors were defined as healthy individuals donating
their kidney to a family member; deceased donors were defined as
patients who have complete and irreversible loss of brain function;
“before reperfusion” was defined as a biopsy after removing the kidney from the donor prior to transplantation; and “after reperfusion”
was defined as a biopsy after kidney transplantation into the recipient.
Renal pathologists, without access to the patient’s clinical data, evaluated these biopsies according to the BANFF renal allograft pathology
classification (67–69). We analyzed serum samples from patients with
histology-proven diagnosis of cellular rejection or engraftment (no
rejection). Blood samples were collected, centrifuged, aliquoted, and
stored at –30°C prior to analysis.
Statistics. Data represent the mean ± SEM prepared using GraphPad Prism software, version 5.0. We used the nonparametric Mann–
Whitney U test to evaluate P values.
Study approval. Use of mice in this study was reviewed and
approved by the Standing Committee on Animals in the Harvard
Medical School, in adherence to standards set in the Guide for the Care
and Use of Laboratory Animals (8th edition, The National Academies
Press, revised 2011). Specimens for human study analysis were taken
from patients after informed consent. The use of these specimens
was approved by the Standing Committee for Clinical Studies of the
Johannes-Gutenberg University, Mainz, Germany, in adherence to the
Declaration of Helsinki and analyzed retrospectively.
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